Matches in SemOpenAlex for { <https://semopenalex.org/work/W1645667097> ?p ?o ?g. }
- W1645667097 endingPage "84" @default.
- W1645667097 startingPage "778" @default.
- W1645667097 abstract "We examined the ability of verapamil, a Ca2+ channel blocker, to overcome Vinca alkaloid and multiple drug resistance in our CEM/VLB100 and CEM/DOX human leukemic lymphoblasts. Compared with the parent CCRF-CEM cells, CEM/VLB100 cells are approximately equal to 200- to 800-fold resistant to vinblastine and express cross-resistance to vincristine, doxorubicin, and other natural product drugs, as determined by comparing 50% inhibitory concentrations in a 48-h growth inhibition assay. Verapamil (10 microM) decreased the 50% inhibitory concentrations for Vinca alkaloids in CEM/VLB100 cells by approximately equal to 75- to 85-fold but caused only slight (approximately equal to 2- to 5-fold) decreases in 50% inhibitory concentrations for anthracyclines, epipodophyllotoxins, and other tubulin-binding drugs (colchicine and podophyllotoxin). Qualitatively similar results were obtained with doxorubicin-resistant cells, termed CEM/DOX; verapamil caused a 19-fold increase in doxorubicin toxicity but 67- and 3500-fold increases in the toxicities of vinblastine and vincristine, respectively. These results indicate that the effect of verapamil is relatively greater for Vinca alkaloids, with less pronounced effects for the other natural product drugs against which these cells express multiple drug resistance. In flow cytometric studies, individually nontoxic or minimally toxic concentrations of vinblastine plus verapamil caused measurable accumulation in the G2 + M phase as early as 4 h after the drug combination was added to cultures of CEM/VLB100 cells; this finding correlated with a comparable increase in the number of cells in mitosis and measurable decreases in the total number of cells. Since similar effects on cell cycle distribution, percentage of cells in mitosis, and cell number were seen when CEM/VLB100 cells were treated with toxic concentrations of vinblastine alone, we conclude that the primary toxicity of the vinblastine-verapamil combination stems from the alkaloid. Further, the rapid lytic effect of the drug combination was associated with cellular vacuolization. The vacuoles did not stain for lipids, and increases in their number were evident within 2 to 4 h after drug treatment. We suggest that verapamil enhances Vinca alkaloid cytotoxicity by altering cryptic cytotoxic targets, possibly related to these vacuoles, through some as yet undefined membrane effect." @default.
- W1645667097 created "2016-06-24" @default.
- W1645667097 creator A5050955474 @default.
- W1645667097 creator A5059387194 @default.
- W1645667097 creator A5059498891 @default.
- W1645667097 creator A5081337406 @default.
- W1645667097 date "1986-02-01" @default.
- W1645667097 modified "2023-09-23" @default.
- W1645667097 title "Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil." @default.
- W1645667097 cites W1492597870 @default.
- W1645667097 cites W1499732389 @default.
- W1645667097 cites W1545285984 @default.
- W1645667097 cites W1569205373 @default.
- W1645667097 cites W1571215201 @default.
- W1645667097 cites W1589379036 @default.
- W1645667097 cites W1595352454 @default.
- W1645667097 cites W1596954277 @default.
- W1645667097 cites W164083597 @default.
- W1645667097 cites W1777887463 @default.
- W1645667097 cites W1970160183 @default.
- W1645667097 cites W1977302028 @default.
- W1645667097 cites W1984516227 @default.
- W1645667097 cites W1984603139 @default.
- W1645667097 cites W1985811545 @default.
- W1645667097 cites W1986421470 @default.
- W1645667097 cites W1989502449 @default.
- W1645667097 cites W2003998013 @default.
- W1645667097 cites W2012306261 @default.
- W1645667097 cites W2014593961 @default.
- W1645667097 cites W2014811932 @default.
- W1645667097 cites W2028533496 @default.
- W1645667097 cites W2031313068 @default.
- W1645667097 cites W2034031399 @default.
- W1645667097 cites W2040816386 @default.
- W1645667097 cites W2046735976 @default.
- W1645667097 cites W2070302413 @default.
- W1645667097 cites W2070990214 @default.
- W1645667097 cites W2073538067 @default.
- W1645667097 cites W2080873944 @default.
- W1645667097 cites W2091269938 @default.
- W1645667097 cites W2096188315 @default.
- W1645667097 cites W2096266792 @default.
- W1645667097 cites W2100875935 @default.
- W1645667097 cites W2107504037 @default.
- W1645667097 cites W2108877577 @default.
- W1645667097 cites W2118069529 @default.
- W1645667097 cites W2149372899 @default.
- W1645667097 cites W2150552611 @default.
- W1645667097 cites W2162807162 @default.
- W1645667097 cites W2163282661 @default.
- W1645667097 cites W2173520866 @default.
- W1645667097 cites W2174557534 @default.
- W1645667097 cites W2406444169 @default.
- W1645667097 cites W2408357934 @default.
- W1645667097 cites W2408993012 @default.
- W1645667097 cites W2416200338 @default.
- W1645667097 cites W2417551405 @default.
- W1645667097 cites W2444049942 @default.
- W1645667097 cites W2469826906 @default.
- W1645667097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3455678" @default.
- W1645667097 hasPublicationYear "1986" @default.
- W1645667097 type Work @default.
- W1645667097 sameAs 1645667097 @default.
- W1645667097 citedByCount "44" @default.
- W1645667097 crossrefType "journal-article" @default.
- W1645667097 hasAuthorship W1645667097A5050955474 @default.
- W1645667097 hasAuthorship W1645667097A5059387194 @default.
- W1645667097 hasAuthorship W1645667097A5059498891 @default.
- W1645667097 hasAuthorship W1645667097A5081337406 @default.
- W1645667097 hasConcept C126322002 @default.
- W1645667097 hasConcept C185592680 @default.
- W1645667097 hasConcept C2776553716 @default.
- W1645667097 hasConcept C2776694085 @default.
- W1645667097 hasConcept C2776755627 @default.
- W1645667097 hasConcept C2777022698 @default.
- W1645667097 hasConcept C2777096885 @default.
- W1645667097 hasConcept C2777132456 @default.
- W1645667097 hasConcept C2777667214 @default.
- W1645667097 hasConcept C2778143360 @default.
- W1645667097 hasConcept C2779429289 @default.
- W1645667097 hasConcept C2781303535 @default.
- W1645667097 hasConcept C519063684 @default.
- W1645667097 hasConcept C71240020 @default.
- W1645667097 hasConcept C71924100 @default.
- W1645667097 hasConcept C86803240 @default.
- W1645667097 hasConcept C98274493 @default.
- W1645667097 hasConceptScore W1645667097C126322002 @default.
- W1645667097 hasConceptScore W1645667097C185592680 @default.
- W1645667097 hasConceptScore W1645667097C2776553716 @default.
- W1645667097 hasConceptScore W1645667097C2776694085 @default.
- W1645667097 hasConceptScore W1645667097C2776755627 @default.
- W1645667097 hasConceptScore W1645667097C2777022698 @default.
- W1645667097 hasConceptScore W1645667097C2777096885 @default.
- W1645667097 hasConceptScore W1645667097C2777132456 @default.
- W1645667097 hasConceptScore W1645667097C2777667214 @default.
- W1645667097 hasConceptScore W1645667097C2778143360 @default.
- W1645667097 hasConceptScore W1645667097C2779429289 @default.
- W1645667097 hasConceptScore W1645667097C2781303535 @default.